In the world of healthcare stocks, it's easy to get caught up in the ebb and flow of the market, but today, I want to take a step back and focus on two ASX healthcare shares that have been on a rollercoaster ride in 2026. These stocks, Epiminder Ltd (ASX: EPI) and Saluda Medical Inc (ASX: SLD), have both seen significant declines this year, but the team at Morgans is predicting a rebound that could see them triple in value over the next year. What makes this particularly fascinating is the potential for these companies to turn things around, despite the challenges they've faced. In my opinion, this is a testament to the resilience and innovation within the healthcare sector, and it raises a deeper question: what are the key factors driving these companies' fortunes, and how can investors navigate the risks and rewards?
Epiminder Ltd (ASX: EPI)
Epiminder is developing the Minder system, a technology that aims to improve epilepsy treatment by continuously recording brain activity data. The company has faced a significant decline in 2026, with its share price falling nearly 50%. However, following its recent quarterly activities report, the team at Morgans has reiterated its speculative buy recommendation. What makes this particularly interesting is the potential for the Minder system to revolutionize epilepsy treatment, and the fact that Epiminder has expanded to 18 Tier-1 US centres and increased enrolled patients to 15. This expansion, combined with the potential for the technology to improve patient outcomes, suggests that Epiminder could be on the cusp of a major breakthrough.
From my perspective, the key to Epiminder's success will be its ability to navigate the regulatory landscape and gain traction in the US market. The company has made significant strides in this area, but there are still challenges to overcome. If Epiminder can continue to build momentum and secure partnerships with healthcare providers, it could be well-positioned to capitalize on the growing demand for innovative epilepsy treatments.
Saluda Medical Inc (ASX: SLD)
Saluda Medical is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions. Its share price has declined nearly 60% year to date, but a fresh price target from Morgans indicates that this could be a buying opportunity. Saluda Medical's quarterly report highlighted revenue growth of 13% QoQ to US$23.8m (+34% YoY), supported by strong growth in implanted patients and active physicians. This strong performance, combined with the company's focus on developing novel neuromodulation platform treatments, suggests that Saluda Medical could be well-positioned to capitalize on the growing demand for advanced medical devices.
One thing that immediately stands out is the potential for Saluda Medical to expand its market reach. The company has a strong presence in the US market, but there is also significant potential for growth in other regions, such as Europe and Asia. If Saluda Medical can successfully expand its market reach, it could be well-positioned to capitalize on the growing demand for its treatments and devices.
Broader Implications and Future Developments
The potential for these two ASX healthcare shares to triple in value over the next year is a fascinating development, but it also raises a deeper question: what are the broader implications for the healthcare sector as a whole? In my opinion, this development suggests that the healthcare sector is undergoing a period of rapid innovation and growth, driven by advancements in technology and a growing demand for advanced medical treatments. This trend is likely to continue, with companies like Epiminder and Saluda Medical leading the way in developing innovative solutions to some of the most pressing healthcare challenges of our time.
Looking ahead, I expect to see more companies in the healthcare sector embracing innovation and investing in research and development. This trend is likely to drive significant growth and opportunity for investors, but it also raises important questions about the risks and rewards of investing in this sector. In my opinion, the key to navigating these risks and rewards will be to focus on companies with strong fundamentals, a clear vision for the future, and a track record of innovation and growth. By doing so, investors can position themselves to capitalize on the exciting opportunities that lie ahead in the healthcare sector.
